Clinical trials: Anthracyclines
Breast Cancer, Metastases
Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer
The purpose of this clinical trial is to determine if RPR109881 is a better treatment than capecitabine (Xeloda) for advanced breast cancer in patients that no longer benefit from docetaxel and/or paclitaxel.
- Trial name
- NCT00081796
- Testing
- larotaxel (RPR109881, XRP9881), capecitabine
- Where
- 187 sites in United States, Argentina and 24 more
- Volunteers
- 438 people
- Sponsor
- Sanofi
Metastatic Breast Cancer
E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
The purpose of this study is to compare E7389 versus capecitabine in patients with locally advanced or metastatic breast cancer who are refractory to the most recent chemotherapy.
- Trial name
- NCT00337103
- Testing
- Eribulin Mesylate, Capecitabine
- Where
- 169 sites in United States, Argentina and 21 more
- Volunteers
- 1,276 people
- Sponsor
- Eisai Inc.
Breast Cancer
Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity
The purpose of this study is to evaluate whether dapagliflozin reduces chemotherapy-induced cardiotoxicity in participants with breast cancer treated with (neo-)adjuvant Anthracycline-based chemotherapy +/- trastuzumab.
- Trial name
- PROTECT (NCT06341842)
- Testing
- Dapagliflozin 10mg Tab
- Where
- Italy
- Volunteers
- 316 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Lymphoma
Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells.
- Trial name
- NCT00016887
- Testing
- filgrastim, recombinant interferon alfa, carmustine
- Where
- 2 sites in Belgium, Italy
- Sponsor
- German Low Grade Lymphoma Study Group
Cardiac Imaging, Cardiac Imaging Techniques
Role of Spectral CT in the Evaluation of Cardiotoxicity in Patients With Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma Treated With Anthracyclines
To evaluate the diagnostic capability of Spectral CT (performed with contrast agent as part of routine oncological follow-up) in detecting signs of acute and chronic early-onset cardiac toxicity from anthracyclines in patients…
- Conditions
- Cardiac Imaging, Cardiac Imaging Techniques, Lymphoma, Hodgkin Disease
- Trial name
- AntraCardioTox (NCT06774326)
- Where
- Italy
- Volunteers
- 160 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Breast Cancer
Genexol-PM Versus Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients
The purpose of this study is to evaluate the overall response rate of Genexol-PM compared with paclitaxel (cremophor-based paclitaxel) as palliative chemotherapy in anthracycline-pretreated patients with metastatic breast cancer.
- Trial name
- NCT01169870
- Testing
- Genexol-PM, Paclitaxel
- Sponsor
- National Cancer Center, Korea
Breast Cancer
Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy
This multicenter clinical study aims to build an intelligent and accurate diagnosis and dynamic prediction and early warning model of cardiotoxicity due to anthracycline-based breast cancer chemotherapy, clarify the value of the…
- Trial name
- NCT06282796
- Testing
- Echocardiography
- Where
- 5 sites in China
- Volunteers
- 600 people
- Sponsor
- First Hospital of China Medical University
Breast Cancer Female
Caloric Restriction and Exercise for Protection From Anthracycline Toxic Effects
Doxorubicin and epirubicin are part of the class of chemotherapy agents called anthracyclines that are commonly used to treat breast cancer.
- Trial name
- CREATE (NCT03131024)
- Testing
- 50% caloric restriction, Aerobic exercise
- Where
- Canada
- Volunteers
- 58 people
- Sponsor
- University of Alberta
Nodal T-follicular Helper Cell Lymphoma
Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell Lymphoma
This is a prospective, multicenter, open-label, single-arm, phase II clinical study to evaluate the safety and efficacy of golidocitinib in combination with an anthracycline-based regimen as first-line treatment for patients with…
- Trial name
- NCT07753642
- Testing
- Golidocitinib, Doxorubicin, Epirubicin
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
Chemotherapy in Treating Patients With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of annamycin liposomal in treating patients who have…
- Trial name
- NCT00012129
- Testing
- liposomal annamycin
- Where
- United States
- Sponsor
- NYU Langone Health
Metastatic Breast Cancer
An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine
The overall purpose of this study is to compare the efficacy, safety and tolerability of indisulam in combination with capecitabine (IC) versus capecitabine (C) monotherapy in patients with metastatic breast cancer who have…
- Trial name
- NCT00165880
- Testing
- E7070
- Where
- 33 sites in Germany, Italy and 3 more
- Volunteers
- 62 people
- Sponsor
- Eisai Limited
Breast Cancer, Left Ventricular Dysfunction
Efficacy of Cardio-Oncology Rehabilitation Exercise for Women With Breast Cancer and Treatment Related Cardiotoxicity
Breast cancer is the leading cause of cancer among Canadian women with nearly 26,000 new cases diagnosed each year. Fortunately, advancements in diagnostic tools and curative treatments have significantly improved overall…
- Conditions
- Breast Cancer, Left Ventricular Dysfunction, Heart Failure, Systolic
- Trial name
- CORE (NCT03089502)
- Testing
- Exercise Rehabilitation
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- University Health Network, Toronto
Lymphoma
Combination Chemotherapy in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Who Have Not Responded to Anthracycline-Containing Combination Chemotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002488
- Testing
- cisplatin, cyclophosphamide, etoposide
- Where
- 2 sites in Canada
- Sponsor
- Ottawa Regional Cancer Centre
Breast Cancer
Pegylated Liposomal Doxorubicin or Epirubicin in Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer.
Pegylated liposomal doxorubicin or epirubicin in neoadjuvant or adjuvant chemotherapy for breast cancer.
- Trial name
- NCT03983096
- Where
- China
- Volunteers
- 1,213 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
NSABP Biospecimen Discovery Project
This study is a biospecimen discovery project that will serve as a pilot for a comprehensive 'omics approach using fresh core biopsy tissue and blood samples for DNA and protein analysis, as well as paired tumor-normal exome DNA…
- Trial name
- NCT01850628
- Testing
- Paclitaxel, trastuzumab, pertuzumab
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- NSABP Foundation Inc
Anthracycline-induced Cardiotoxicity
Preventing Cardiac Sequelae in Pediatric Cancer Survivors
Cancer therapy can place childhood cancer survivors at increased risk for heart disease which can lead to significant illness or early death.
- Trial name
- PCS2 (NCT01805778)
- Where
- 6 sites in United States, Canada
- Volunteers
- 1,128 people
- Sponsor
- The Hospital for Sick Children
Lymphoma, High-Grade
Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL
Phase II study for treatment of patients with relapsed or primary refractory aggressive B- cell NHL and anthracycline chemotherapy pretreatment, who received or did not qualify for autologous stem cell transplantation.
- Trial name
- NCT00385125
- Testing
- Bendamustine, Rituximab
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University of Magdeburg
Cardiac Toxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as enalapril, may protect normal cells from the toxic effects of chemotherapy.
- Trial name
- NCT00003070
- Testing
- enalapril maleate, quality-of-life assessment
- Where
- 61 sites in United States, Canada and 1 more
- Volunteers
- 13 people
- Sponsor
- Children's Oncology Group
Breast Cancer
Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer
The increasing use of anthracyclines and taxanes in the adjuvant, neoadjuvant and first-line metastatic settings, led to a raise of patients presenting with metastatic breast cancer after treatment with these agents.
- Trial name
- NCT01095003
- Testing
- Vinflunine plus Capecitabine, Capecitabine
- Where
- 110 sites in Argentina, Belarus and 19 more
- Volunteers
- 770 people
- Sponsor
- Pierre Fabre Medicament
Breast Neoplasms, Adjuvant
Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer
Anthracycline based regimens followed by a taxane (CALGB-9344 trial and NSABP-B28) or reversed (MD Anderson Adjuvant Trial) has already accepted as adjuvant therapy for node positive breast cancer.
- Conditions
- Breast Neoplasms, Adjuvant, Chemotherapy
- Trial name
- NCT00525642
- Testing
- Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide
- Where
- 5 sites in China
- Volunteers
- 603 people
- Sponsor
- Fudan University